Zydus Lifesciences Limited has informed the Exchange about addendum to the Public Announcement for the buyback of equity shares
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty 100 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences has issued an addendum to its buyback announcement, increasing the buyback price from INR 1,150 to INR 1,260 per share (a 9.57% increase). Simultaneously, the maximum number of shares to be bought back has been reduced from 95,65,217 to 87,30,158 shares (approximately 0.87% of paid-up capital). The total buyback amount remains capped at INR 1,100 crore. The Buyback Committee approved these changes on May 27, 2026. An addendum to the Public Announcement will be published in major newspapers and on the company, manager, and SEBI websites.
The higher buyback price improves returns for shareholders who tender their shares, making the offer more attractive. The reduced number of shares being bought back could slightly limit the total shareholder returns compared to the original plan.